Citations (14)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Yuyuan Zhang, Zaoqu Liu, Jie Li, Xin Li, Mengjie Duo, Siyuan Weng, Peijie Lv, Guozhong Jiang, Caihong Wang, Yan Li, Shichao Liu & Zhen Li. (2023) Prognosis and Personalized Treatment Prediction in Different Mutation-Signature Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma 10, pages 241-255.
Read now
Read now
Yanan Tan, Kangna Cao, Guanghui Ren, Zhiying Qin, Di Zhao, Ning Li, Xijing Chen, Yufeng Xia & Yang Lu. (2020) Effects of the ABCB1 and ABCG2 polymorphisms on the pharmacokinetics of afatinib in healthy Chinese volunteers. Xenobiotica 50:2, pages 237-243.
Read now
Read now
Ana Marija Sola, Daniel E. Johnson & Jennifer R. Grandis. (2019) Investigational multitargeted kinase inhibitors in development for head and neck neoplasms. Expert Opinion on Investigational Drugs 28:4, pages 351-363.
Read now
Read now
Cristiana Lo Nigro, Nerina Denaro, Anna Merlotti & Marco Merlano. (2017) Head and neck cancer: improving outcomes with a multidisciplinary approach. Cancer Management and Research 9, pages 363-371.
Read now
Read now
Articles from other publishers (10)
Fruzsina Kiss, Krisztina Pohóczky, Anikó Görbe, Fanni Dembrovszky, Szabolcs Kiss, Péter Hegyi, Lajos Szakó, Lilla Tóth, Éva Somogyiné Ezer, Eszter Szalai & Zsuzsanna Helyes. (2022) Addition of epidermal growth factor receptor inhibitors to standard chemotherapy increases survival of advanced head and neck squamous cell carcinoma patients: A systematic review and meta‐analysis. Oral Diseases 29:5, pages 1905-1919.
Crossref
Crossref
Lin Dong, Yu Wang, Xiaofeng Yao, Yu Ren & Xuan Zhou. (2022) Novel Insights of Anti-EGFR Therapy in HNSCC: Combined with Immunotherapy or Not?. Current Oncology Reports 25:2, pages 93-105.
Crossref
Crossref
Subramanya Pandruvada, Remi Kessler & Ann Thai. 2023.
205
252
.
Sanjib Chaudhary, Imayavaramban Lakshmanan, Apar Kishor Ganti, Muzafar A. Macha & Surinder K. Batra. (2022) Reply. Cancer Letters 527, pages 193-194.
Crossref
Crossref
Laveniya Satgunaseelan, Sean Porazinski, Dario Strbenac, Aji Istadi, Cali Willet, Tracy Chew, Rosemarie Sadsad, Carsten E. Palme, Jenny H. Lee, Michael Boyer, Jean Y. H. Yang, Jonathan R. Clark, Marina Pajic & Ruta Gupta. (2021) Oral Squamous Cell Carcinoma in Young Patients Show Higher Rates of EGFR Amplification: Implications for Novel Personalized Therapy. Frontiers in Oncology 11.
Crossref
Crossref
Bhamini Patel & Nabil F. Saba. (2021) Current Aspects and Future Considerations of EGFR Inhibition in Locally Advanced and Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck. Cancers 13:14, pages 3545.
Crossref
Crossref
Gh. Rasool Bhat, Rosalie G. Hyole & Jiong Li. 2021.
67
102
.
Zhicheng Su, Tingyuan Yang, Jie Wang, Mengzhen Lai, Linjiang Tong, Gulinuer Wumaier, Zhuo Chen, Shengqing Li, Honglin Li, Hua Xie & Zhenjiang Zhao. (2020) Design, synthesis and biological evaluation of potent EGFR kinase inhibitors against 19D/T790M/C797S mutation. Bioorganic & Medicinal Chemistry Letters 30:16, pages 127327.
Crossref
Crossref
Elham Alsahafi, Katheryn Begg, Ivano Amelio, Nina Raulf, Philippe Lucarelli, Thomas Sauter & Mahvash Tavassoli. (2019) Clinical update on head and neck cancer: molecular biology and ongoing challenges. Cell Death & Disease 10:8.
Crossref
Crossref
Cory D. Fulcher, Missak HaigentzJrJr & Thomas J. Ow. (2018) AHNS Series: Do you know your guidelines? Principles of treatment for locally advanced or unresectable head and neck squamous cell carcinoma. Head & Neck 40:4, pages 676-686.
Crossref
Crossref